Skip to Main Content

Author Details

Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
1993
70
31
PMIDPaper TitleJournal TitlePublished Year
36264026Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.Br J Haematol2023
37182843CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.Br J Haematol2023
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
36734985Oncoproteomic profiling of AML: moving beyond genomics.Expert Rev Proteomics2022
36307214Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.Cold Spring Harb Mol Case Stud2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
35896960Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.Clin Proteomics2022
34813325Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality.J Am Soc Mass Spectrom2022
33403501NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.Invest New Drugs2021
33563661Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.Cancer Discov2021
33780043A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.Am J Hematol2021
34222745<i>Ex Vivo</i> Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.Annu Rev Cancer Biol2021
34302041Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.NPJ Precis Oncol2021
34171263The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer Cell2021
32366937ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.Leukemia2020
31980503Functional characterization of two rare BCR-FGFR1<sup>+</sup> leukemias.Cold Spring Harb Mol Case Stud2020
31880950Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.J Clin Oncol2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
32754299Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.Oncotarget2020
32296029NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2[V617F]-positive myeloproliferative neoplasm cells.Signal Transduct Target Ther2020
32513686Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.Proc Natl Acad Sci U S A2020
32315394Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.Blood2020
30642575Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.Leuk Res2019
31551508Revisiting NTRKs as an emerging oncogene in hematological malignancies.Leukemia2019
31543464Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.Cancer Cell2019
31048320The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.Cancer Discov2019
29472557Metformin exerts multitarget antileukemia activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasms.Cell Death Dis2018
30082821Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Leukemia2018
29903916Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.J Biol Chem2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
29391602Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.Oncogene2018
28630439Recurrent cyclin D2 mutations in myeloid neoplasms.Leukemia2017
28181280Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples.Am J Hematol2017
28208123Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.Oncotarget2017
28784769Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Proc Natl Acad Sci U S A2017
28906323Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.J Pediatr Hematol Oncol2017
26755644IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.Oncotarget2016
27118405Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.Leukemia2016
25109334Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Oncogene2015
26870618Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.Cureus2015
26032424Therapeutically Targetable ALK Mutations in Leukemia.Cancer Res2015
25965573Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.Cancer Cell2015
25631473Detecting and targetting oncogenic fusion proteins in the genomic era.Biol Cell2015
23499551Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis.Am J Pathol2013
24218589Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.Proc Natl Acad Sci U S A2013
23656643Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.N Engl J Med2013
23798677Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation.J Biol Chem2013
23706743The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.Cell2013
23783032The PI3K/Akt1 pathway enhances steady-state levels of FANCL.Mol Biol Cell2013
21804605A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.Oncogene2012
  • 1 - 50 of 70

Recommended Authors

Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 8
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 6
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 22
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 4
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 5
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 1
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 3
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 3
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 4
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 3
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 1
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 13
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 1
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Career Start Year 1994
Number of shared co-authors 1
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 1
Aykut Uren
Georgetown University Medical Center
Career Start Year 1991
Number of shared co-authors 5
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 17
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 2
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 15
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 10
Choh Yeung
Center for Cancer Research, National Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 14
Jeffrey A Toretsky
Georgetown University Medical Center, Georgetown University
Career Start Year 1986
Number of shared co-authors 10
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 10
Andrew D Cherniack
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 8
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Career Start Year 1984
Number of shared co-authors 20

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 38
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 30
Poul H Sorensen
British Columbia Cancer Research Centre
Co-authored papers 22
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 18
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 15
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 11
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 11
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 8
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Sunil K Joshi
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Elie Traer
Oregon Health & Science University
Co-authored papers 8
Monika A Davare
Oregon Health Sciences University
Co-authored papers 7
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 7
Nicola Long
Oregon Health and Science University
Co-authored papers 6
Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 6
Bill H Chang
Oregon Health and Science University
Co-authored papers 6
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 6
Uma Borate
The Ohio State University
Co-authored papers 6
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 5
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 5
Karin D Rodland
Oregon Health and Science University
Co-authored papers 4
Alexey V Danilov
City of Hope National Medical Center
Co-authored papers 4
Pierrette Lo
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Barak Rotblat
Ben-Gurion University of the Negev
Co-authored papers 3
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 3
Release 1.2